Additional file 2 of Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients
Creators: name: Ilseon Hwang
name: Kim, Jeong Won
name: Ylaya, Kris
name: Chung, Eun Joo
name: Haruhisa Kitano
name: Perry, Candice
name: Hanaoka, Jun
name: Fukuoka, Junya
name: Chung, Joon-Yong
name: Hewitt, Stephen M.
Publisher: name: figshare
Year: 2020
Subjects: subject: Biochemistry
subject: Space Science
subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Pharmacology
subject: 69999 Biological Sciences not elsewhere classified
subject: Cancer

description: Additional file 2: Fig. S1 Association between tumor-associated macrophage and VEGFs in human non-small cell lung cancer (NSCLC). Correlation between tumor-associated macrophage and VEGF-A (a) and VEGF-C (b). Fig. S2 Correlation among tumor-associated macrophage-, angiogenesis- and lymphangiogenesis-related markers in patients with adenocarcinoma NSCLC. CD68 expression positively correlated with CD163 (a), VEGF-A (b), and VEGF-C (c) expression. CD163 expression showed a significant positive correlation with VEGF-A (d), but a weak correlation with VEGF-C (e) expression. There is a positive correlation between VEGF-A and VEGF-C (f). Fig. S3 Correlation among tumor-associated macrophage-, angiogenesis- and lymphangiogenesis-related markers in patients with squamous cell carcinoma NSCLC. CD68 expression positively correlated with CD163 (a), VEGF-A (b), and VEGF-C (c) expression. CD163 expression showed a moderate correlation with VEGF-A (d) and VEGF-C (e) expression. There is a significant positive correlation between VEGF-A and VEGF-C (f). Fig. S4 Kaplan–Meier survival curves for tumor-associated macrophage-, angiogenesis- and lymphangiogenesis-related markers in NSCLC patients with adenocarcinoma. Patients expressing CD68 had better overall survival than patients who did not (OS rate, 85.9% vs. 75.7%, log rank p = 0.034) (a), while CD163 was not associated with patient survival (p = 0.470) (b). Patients with a high M2 ratio (CD163/CD68) had significantly shorter overall survival than patients with a low M2 ratio (OS rate, 76.0% vs. 84.5%, log rank p = 0.047) (c). There were no meaningful overall survival differences for VEGF-A (p = 0.092) (d) and VEGF-C (p = 0.899) (e) expression in NSCLC patients. Fig. S5 Kaplan–Meier survival curves for tumor-associated macrophage-, angiogenesis- and lymphangiogenesis-related markers in NSCLC patients with squamous cell carcinoma. There were no meaningful overall survival differences for CD 68 (p = 0.153) (a), CD163 (p = 0.449) (b), M2 ratio (p = 0.682) (c), VEGF-A (p = 0.091) (d) and VEGF-C (p = 0.670) (e) expression in NSCLC patients with squamous cell carcinoma. Fig. S6 Survival analysis of NSCLC patients with M2 ratio expression according to angiogenesis (VEGF-A) or lymphangiogenesis (VEGF-C) marker expression in NSCLC patients with adenocarcinoma. Survival differences were observed among 4 NSCLC patient groups classified according to their M2 ratio and VEGF-A expression (log rank p = 0.027) (a). A significant difference of survival rate was found among 4 NSCLC patient groups classified according to their M2 ratio and VEGF-C expression (log rank p = 0.042) (b). Fig. S7 Survival analysis of NSCLC patients with M2 ratio expression according to angiogenesis (VEGF-A) or lymphangiogenesis (VEGF-C) marker expression in NSCLC patients with squamous cell carcinoma. There were no meaningful overall survival differences for combination M2 ratio and VEGF-A (p = 0.387) (a) or VEGF-C (p = 0.551) (b).